Long‐term follow‐up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia

Most clinical trials for acute leukemia have reported results after 2‐3 years of follow‐up. Comparisons between the original data and longer‐term follow‐up data may be of interest, particularly with regard to promising new therapies.

[1]  L. Doyle,et al.  Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. , 1995, Biochemical pharmacology.

[2]  A. Bartolucci,et al.  A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Berman,et al.  Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. , 1992, Blood.

[4]  P. Ritch,et al.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia , 1992 .

[5]  Janice Gabrilove,et al.  Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia , 1991 .

[6]  N. Winick,et al.  Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. , 1987, Cancer Research.

[7]  C. Haanen,et al.  Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4‐demethoxydaunomycin , 1986, Clinical pharmacology and therapeutics.

[8]  A. Marmont,et al.  4‐Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study , 1985, Cancer.

[9]  B. Leyland-Jones,et al.  Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. , 1985, Cancer research.